ESC 2021: Late-breaking Science Video Collection
Published: 02 September 2021
Part 3 | Session 2 SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
Part 3 | Session 3 TWILIGHT-HBR: Ticagrelor Monotherapy in HBR Patients Undergoing PCI
Part 3 | Session 4 The LAAOS III Study: Surgical AFIB Ablation Evaluation
Part 3 | Session 5 TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
Part 3 | Session 6 STOPDAPT-2 ACT: 1-Month DAPT Followed by Clopidogrel Monotherapy in ACS
Part 3 | Session 7 SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
Part 3 | Session 9 VOYAGER PAD: Rivaroxaban in Symptomatic PAD With & Without Comorbid Diabetes
Part 3 | Session 10 Micra CED: 2-Year Outcomes with Leadless Pacing
Part 3 | Session 11 RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviewed principal investigators on their studies, learnings, and applicability to clinical practice in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
View from the Thoraxcenter
Late-breaker Discussion Series
Masterclass with Dr Harriette Van Spall & Dr Birgit Vogel
Nicolas M Van Mieghem
From an early age, Professor Nicolas Maria Van Mieghem decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them. I wanted to enter a profession that would channel my energy— I was always a busy child,” he says.
A budding athlete, he was a member of Belgium’s national swimming team but soon realized that medicine was his true calling. His father was a general cardiologist and one of his biggest influences early in his career.
Professor Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002.
His mantra is mens sana in corpore sano (a…
Dr Joost Daemen, MD, PhD obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of 4 trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.